Published on in Vol 5, No 3 (2016): Jul-Sept

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

Angela E Rankine-Mullings 1, MBBS, MRCPCH;  Courtney R Little 2, RN, BSN;  Marvin E Reid 3, MBBS, PhD;  Deanne P Soares 3, MBBS, DM;  Carolyn Taylor-Bryan 3, MBBS, DM;  Jennifer M Knight-Madden 1, MBBS, PhD;  Susan E Stuber 2, MA;  Asha V Badaloo 3, PhD;  Karen Aldred 1, MSc;  Margaret E Wisdom-Phipps 1, RN, RM;  Teresa Latham 2, MA;  Russell E Ware 2, MD, PhD

1 Sickle Cell Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston , JM

2 Division of Hematology , Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, US

3 Tropical Metabolism Research Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston , JM

Corresponding Author: